Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study

What Was Tested

The paper reports a study of Insulin Aspart and NPH Insulin (isophane), published as a clinical trial.

Who Took Part

The study group was 66,726 people.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as open-label and multicenter.

Nothing was hidden in this open-label Insulin Aspart study: the people and staff both knew the treatment.

More than one site took part, so the people came from several places.

The study was conducted in 28 countries across Asia, Africa, Latin America, and Europe.

Here, the researchers report data from a subgroup of 762 people with T2DM from the Pakistani cohort (insulin naïve and insulin users) who were treated withpremix insulin (BIAsp 30) +/- oral antidiabetic drugs (OADs).

What Was Measured

The subject headings attached to it are Biological Availability, Biphasic Insulins, Blood Glucose, Blood Pressure, Cholesterol, Diabetes Mellitus, Type 2 and Drug Evaluation.

What This Means in Plain Language

The paper is an open-label and multicenter study of Insulin Aspart and NPH Insulin (isophane) in 66,726 people.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (JPMA. The Journal of the Pakistan Medical Association), a journal based in Pakistan.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page, all human trials.